The GLP-1 boom: why Mounjaro and Wegovy are reshaping the pharmacy market

Pharmafit Provence lists all strengths of Mounjaro (tirzepatide, Eli Lilly) and Wegovy (semaglutide, Novo Nordisk). Every product can be ordered through our team.

From a diabetes treatment category to a global phenomenon

In just a few quarters, GLP-1 analogues have become the most dynamic therapeutic class in recent pharmaceutical history. Initially launched for type 2 diabetes, semaglutide (Ozempic, Rybelsus, then Wegovy for obesity), followed by tirzepatide (Mounjaro, a dual GLP-1/GIP agonist), opened a market that neither manufacturers nor public authorities had anticipated on this scale.

The figures show a sharp change in trajectory:

• Novo Nordisk exceeds $40 billion in annual revenue from its GLP-1 franchise, driven by Wegovy and Ozempic.
• Eli Lilly has taken Mounjaro to the status of the decade's leading blockbuster molecule, with triple-digit quarterly growth in some regions.
• In France, community pharmacies are seeing GLP-1 treatments enter the top five medicines dispensed by value.

Why the surge: a rare combination of factors

This growth is no passing trend. Several forces are converging:

1. Unprecedented clinical efficacy for weight loss — average weight reduction of 15–22% across trials, compared with 5–8% for older obesity treatments.
2. Demonstrated cardiovascular benefit (the SELECT study for semaglutide), extending prescribing beyond diabetes alone.
3. Gradually expanding indications: heart failure, diabetic kidney disease, sleep apnoea, MASH (NASH), with addiction treatments under investigation.
4. Worldwide social and media pressure, turning demand into a sustained movement, particularly visible in the United States and northern Europe.
5. Industrial expansion of supply: Eli Lilly and Novo Nordisk are investing over $20 billion combined in production capacity to meet demand by 2027.

For community pharmacies: a category that changes everything

Community pharmacists are on the front line:

• Strongly rising volumes: a GLP-1 patient represents an average of 13 packs a year (4 pens × week × 13 cycles), resulting in a four-figure annual spend per patient.
• Long-term patient retention: prescribing is continuous and adherence is critical. The pharmacy becomes a monthly point of contact.
• A core category: GLP-1 treatments are quickly becoming a major contributor to pharmacy turnover and patient retention.
• Pressure on margins: high prices require substantial working capital and close attention to purchasing terms.

2026 market outlook: where is the market heading?

Our assessment for the next 18 months:

• Industrial supply ramp-up in the second half of 2026 as new capacity comes online.
• New entrants: oral treatments (high-dose semaglutide), retatrutide (Lilly, a triple agonist), CagriSema (Novo) — competition is intensifying.
• A shift towards reimbursement for obesity in several European countries, potentially doubling French volumes by 2027.
• Regulatory risk around off-label and cosmetic uses that pharmacies need to screen carefully.

For pharmacists, the right step is to secure a competitive, reliable supply channel now for this increasingly strategic category.

Pharmafit Provence terms for GLP-1 treatments

We have made GLP-1 analogues a commercial priority. In practice:

• All Mounjaro and Wegovy products in our catalogue.
• Highly competitive pricing for this specific category, with a weighted discount clearly shown on the invoice.
• 11 pm cut-off for next-day delivery across Provence and the wider south-east.
• 2–8°C cold chain monitored from end to end — critical for these medicines.

How to order

The easiest way is to message us directly on WhatsApp with your RPPS / pharmacy FINESS number. During business hours, we reply within minutes with net prices and account setup terms if you are not yet a customer.

You can also call us on +33 4 65 84 82 46 or email provence@pharmafit.fr.